Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.47 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313488 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL6313490 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8184231 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8184232 | 1.00 | NT5E (1.00) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8928824 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL9164604 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8928920 | 0.99 | NT5E (0.98) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11418144 | 0.96 | NT5E (0.93) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11418140 | 0.96 | NT5E (0.93) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL21749232 | 0.91 | NT5E (0.84) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430032-B1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MAN GMBH & CO KG (DE) | 2016-02-17 | — | — | EP | disclosed |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2012-08-30 | — | — | US | disclosed |
| EP-2430032-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | Alcafleu Management GmbH & Co. KG (DE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130778-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-5747465-A | Sugar derivatives of macrolides | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0629209-B1 | SUGAR DERIVATIVES OF MACROLIDES | PFIZER (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0456817-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS INC (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5296589-A | Dissolving in nonreactive solvent, reacting with hydrogen, palladium chloride, hydrochloric acid in sealed vessel at elevated pressure, removing palladium chloride, neutralizing, separating product | ASH STEVENS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5110919-A | Economical preparation of nucleosides | ASH STEVENS, INC. (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0456817-A4 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | — | 1992-04-22 | — | — | EP | disclosed |
| EP-0456817-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES. | ASH STEVENS INC (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1991008215-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4188378-A | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | CD38, FLAD1, GART | NT5E 1122/4885PTPN1 4843/4885CDC25B 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.